Skip Navigation


CIT can broadcast your seminar, conference or meeting live to a world-wide audience over the Internet as a real-time streaming video. The event can be recorded and made available for viewers to watch at their convenience as an on-demand video or a downloadable file. CIT can also broadcast NIH-only or HHS-only content.

The event ended, check back after it has been posted to the Past Events section.

 

PROTAC-Mediated Protein Degradation: A New Therapeutic Modality (HHS Only)

   
Air date: Wednesday, November 6, 2019, 3:00:00 PM
Time displayed is Eastern Time, Washington DC Local
Description: NIH Director’s Wednesday Afternoon Lecture Series

Crews' innovative work draws upon a palette of disciplines that includes cell biology, biochemistry, pharmacology, medicinal and organic chemistry. Crews co-developed Proteolysis Targeting Chimera (PROTACs), which represent a new class of clinical drug candidates that work via a targeted protein degradation. His work served as a basis for the development of the multiple myeloma drug Carfilzomib.

The ability to control protein levels using PROTACs is changing how drugs are being developed and is expanding our concept of the druggable target space. Moreover, PROTACs offer the advantages of siRNA but with more favorable pharmaceutical properties (ADME, biodistribution, routes of administration). For the past 20 years, Dr. Crews has pioneered the development of this new modality from concept to clinical trials. Here he will describe the current and future trends in this fast-paced, exciting new therapeutic field.

The aforementioned palette of disciplines that includes cell biology, biochemistry, pharmacology, medicinal and organic chemistry implies this lecture will be of broad interest to the NIH community. There's something for everyone.

For more information go to https://oir.nih.gov/wals
Author: Craig M. Crews, Ph.D., Professor, Molecular, Cell and Developmental Biology, Yale University
Runtime: 1 hour